» Articles » PMID: 36291815

Radiotherapy-Related Gene Signature in Prostate Cancer

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Oct 27
PMID 36291815
Authors
Affiliations
Soon will be listed here.
Abstract

Radiotherapy for localized prostate cancer has increased the cure and survival rates of patients. Besides its local tumoricidal effects, ionizing radiation has been linked to mechanisms leading to systemic immune activation, a phenomenon called the abscopal effect. In this study, we performed gene expression analysis on peripheral blood from prostate cancer patients obtained post- radiotherapy and showed that 6 genes, including , , , , , and , were down-regulated by a range of 1.5-2.5-fold as compared to pre-radiotherapy samples. The expression of the signature consisting of these six genes was also significantly lower post- vs. pre-radiotherapy. These genes are involved in various tumor-promoting immune pathways and their down-regulation post-radiotherapy could be considered beneficial for patients. This is supported by the fact that low mRNA expression levels for the 6-gene signature in the prostate tumor tissue was linked to better survival. Importantly, we report that this 6-gene signature strongly correlated with a favorable prognosis regardless of poor standard clinicopathological parameters (i.e., Gleason score ≥ 8 and T3 (including T3a and T3b). Our pioneering data open the possibility that the 6-gene signature identified herein may have a predictive value, but this requires further long-term studies.

Citing Articles

Integrating Radiosensitivity Index and Radiation Resistance Related Index Improves Prostate Cancer Outcome Prediction.

Wu Q, Yin Z, Zhang Y, Lin Y, Jiang J, Zheng R Adv Radiat Oncol. 2025; 10(3):101713.

PMID: 40034476 PMC: 11872654. DOI: 10.1016/j.adro.2025.101713.


FCGR2B as a prognostic and immune microenvironmental marker for gliomas based on transcriptomic analysis.

Sun Z, Sun X, Yuan Y, Li H, Li X, Yao Z Medicine (Baltimore). 2023; 102(37):e35084.

PMID: 37713871 PMC: 10508392. DOI: 10.1097/MD.0000000000035084.


Correction: Kogionou et al. Radiotherapy-Related Gene Signature in Prostate Cancer. 2022, , 5032.

Kogionou P, Fortis S, Goulielmaki M, Aubert N, Batsaki P, Ouzounis S Cancers (Basel). 2023; 15(14).

PMID: 37509413 PMC: 10377781. DOI: 10.3390/cancers15143616.


A Blood-Based Immune Gene Signature with Prognostic Significance in Localized Prostate Cancer.

Fortis S, Batsaki P, Stokidis S, Moschandreou D, Grouzi E, Baxevanis C Cancers (Basel). 2023; 15(14).

PMID: 37509358 PMC: 10377824. DOI: 10.3390/cancers15143697.

References
1.
Baxevanis C, Gritzapis A, Voutsas I, Batsaki P, Goulielmaki M, Adamaki M . T-Cell Repertoire in Tumor Radiation: The Emerging Frontier as a Radiotherapy Biomarker. Cancers (Basel). 2022; 14(11). PMC: 9179913. DOI: 10.3390/cancers14112674. View

2.
DAuria F, Statuto T, Rago L, Montagna A, Castaldo G, Schiro I . Modulation of Peripheral Immune Cell Subpopulations After RapidArc/Moderate Hypofractionated Radiotherapy for Localized Prostate Cancer: Findings and Comparison With 3D Conformal/Conventional Fractionation Treatment. Front Oncol. 2022; 12:829812. PMC: 9198604. DOI: 10.3389/fonc.2022.829812. View

3.
Ruth J, Gurrea-Rubio M, Athukorala K, Rasmussen S, Weber D, Randon P . CD6 is a target for cancer immunotherapy. JCI Insight. 2021; 6(5). PMC: 8021120. DOI: 10.1172/jci.insight.145662. View

4.
Derre L, Rivals J, Jandus C, Pastor S, Rimoldi D, Romero P . BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest. 2009; 120(1):157-67. PMC: 2799219. DOI: 10.1172/JCI40070. View

5.
Wang X, Wu D, Chen W, Liu J, Ju Y . Impact of radiotherapy on immunological parameters, levels of inflammatory factors, and clinical prognosis in patients with esophageal cancer. J Radiat Res. 2019; 60(3):353-363. PMC: 6530619. DOI: 10.1093/jrr/rrz006. View